Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases

World Journal of Surgery

Volumn 40, Issue 5, 2016, Pages 1178-1190

  Bhutiani, Neal ^a   Akinwande, Olaguoke ^a   Martin, Robert C G ^a  

^a Upper Gastrointestinal and Hepato Pancreatico Biliary Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; IRINOTECAN;

ADULT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84951965640     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-015-3386-9     Document Type: Article

References (37)

1. Jones RPDD, Sutton P et al (2013) Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumous destruction: a case-control series. HPB 15:71-77
2. Jones RPSP, Greensmith RMD et al (2013) Hepatic activation of irinotecan predicts tumous response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study. Cancer Chemoth Pharmacol 72:359-368
3. Martin RCGHJ, Tomalty D et al (2010) Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Interv Radiol 33:960-966
4. Martin RCGJJ, Robbins K et al (2009) Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 29:1-6
5. Martin RCGSC, Tomalty D et al (2012) Irinotecan drug-eluting beads in the treatment of chemo-naïve unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16:1531-1538
6. Narayanan GBK, Suthar R et al (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33:2077-2084
7. Richardson AJ, Laurence JM, Lam VW (2013) Transarterioal chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol: JVIR 24:1209-1217
8. Martin RC, 2nd, Scoggins CR, Schreeder M et al (2015) Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer
9. Jm C (1989) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504
10. Rothenberg MLCJ, DeVore RF et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795
11. Rothenberg MLEJ, Kuhn JG et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135
12. Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418
13. Rougier PVCE, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
14. Zhao Z, Pelletier E, Barber B et al (2012) Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin 28:221-229
15. Benson AB, 3rd, Bekaii-Saab T, Chan E et al (2013) Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw: JNCCN 11:141-152; quiz 52
16. Chen HXMM, Boron M et al (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24:3354-3360
17. Cunningham DHY, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
18. de Gramont AVJ, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219
19. Hecht JR, Cohn AL, Dakhil S et al (2013) SPIRITT (study 2006014): a randomized phase II study of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Gastrointest Canc Sympos
20. Park SHSJ, Han SH et al (2005) Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. Jpn J Clin Oncol 35:531-535
21. Peeters MPT, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713
22. Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21
23. Saltz LBLH, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557-4561
24. Seymour MTBS, Middleton G et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14:749-759
25. Sobrero AFMJ, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319
26. Ulrich-Pur HKG, Fiebiger W et al (2001) Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 12:1269-1272
27. Fiorentini GAC, Tilli M et al (2012) Intra-arterial Infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:1387-1396
28. Jones RPSS, Dunne DFJ et al (2013) Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI) for colorectal liver metastases does not predict tumous destruction or ong-term outcome. EJSO 39:1122-1128
29. Martin RCGJJ, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectal colorectal liver mesatases refractiory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18:192-198
30. Martin RCGRK, Tomalty D et al (2009) Transarterial chemoemblization (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7:80
31. Lencioni R, Aliberti C, de Baere T et al (2014) Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol: JVIR 25:365-369
32. Eisenhauer EATP, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
33. Llovet JM, Brú C, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711
34. Martin RCGSR, Adam R, Dixon R (2013) Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement. HPB 15:131-133
35. Bower M, Metzger T, Robbins K et al (2010) Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB: Off J Int Hepato Pancreato Biliary Assoc 12:31-36
36. Brown RE, Bower MR, Metzger TL et al (2011) Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? HPB: Off J Int Hepato Pancreato Biliary Assoc 13:91-95
37. Fiorentini GAC, Mulazzani L et al (2014) Chemoembolication in colorectal liver metastases: the rebirth. Anticancer Res 34:575-584